# OnCo record antares-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/antares-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "antares-therapeutics" ;
  schema:name "Antares Therapeutics"@en ;
  schema:description "Antares Therapeutics is a Boston and South San Francisco company spun out of Scorpion Therapeutics to make small-molecule cancer drugs against targets long considered undruggable. Its first medicine, ATX-898, entered a phase 1/2 trial in 2026, and Novartis signed a discovery deal with it in June 2026."@en ;
  schema:url <https://onco.cc/companies/antares-therapeutics/>, <https://antaresrx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://antaresrx.com/>, <https://antaresrx.com/antares-therapeutics-enters-agreement-with-novartis-to-discover-develop-and-commercialize-first-in-class-cancer-therapies/>, <https://www.fiercebiotech.com/biotech/scorpion-spinout-raises-177m-advance-preclinical-assets-after-2-clinical-programs-sold>, <https://clinicaltrials.gov/study/NCT07767474> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/scorpion-therapeutics/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/pierre-fabre/> .